Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer Gao, Tatiana M. Prowell, Joyce Cheng et al.|The Lancet Oncology|2019Cited by 299
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Sundeep Agrawal et al.|The Oncologist|2018Cited by 200
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Julia A. Beaver, Lijun Zhang et al.|Clinical Cancer Research|2020Cited by 186
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Sakar Wahby et al.|Clinical Cancer Research|2020Cited by 185